不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入治疗术后的影响

Study on the effects of different doses of rosuvastatin on patients with acute myocardial infarction after percutaneous coronary intervention

目的:探讨不同剂量瑞舒伐他汀对急性心肌梗死患者经皮冠状动脉介入(PCI)治疗术后的影响。方法:分析300例急性心肌梗死经皮冠状动脉介入治疗患者临床资料,依据治疗药物剂量不同进行分组,治疗Ⅰ组120例和治疗Ⅱ组180例。于术前、术后7d,观察两组患者的炎症因子[高敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)]及心功能指标[左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左室射血分数(LVEF)]情况。结果:术后7d,两组患者hs-CRP、TNF-α、IL-6水平均降低,且治疗Ⅱ组降低更为明显(P<0.05);两组患者LVESD降低、LVEF升高,且治疗Ⅱ组变化更为明显(P<0.05);两组术前、术后组内、组间LVEDD水平比较,差异无统计学意义(P<0.05)。两组均未出现明显不良反应。结论:高剂量瑞舒伐他汀应用于急性心肌梗死PCI术患者中,能够有效降低炎症因子水平,改善心功能。

Objective:To investigate the effects of different doses of rosuvastatin on patients with acute myocardial infarction after percutaneous coronary intervention(PCI).Methods:The clinical data of 300 patients with acute myocardial infarction treated by percutaneous coronary intervention were analyzed.They were grouped according to the dose of rosuvastatin used.Ⅰlow-dose treatment group 120 cases andⅡhigh dose treatment group 180 examples.Inflammatory factors including high-sensitivity C-reactive protein(HS-CRP),tumor necrosis factor-(TNF-),and interleukin-6(IL-6)were observed before and 7 days after surgery in both groups.And cardiac function indicators,including left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),and left ventricular ejection fraction(LVEF).Results:After seven days,two groups of patients with hs CRP,TNF alpha,IL-6 levels are reduced,and the treatmentⅡgroup decreased significantly(P<0.05).LVESD reduced,LVEF increased in both groups,and changeⅡtreatment group was more obvious(P<0.05).Comparison of LVEDD levels in and between the two groups before and after operation showed no statistically significant difference(P<0.05).No obvious adverse reactions occurred in both groups.Conclusion:PCI for acute myocardial infarction USES high-dose rosuvastatin,which can effectively reduce the level of inflammatory factors and improve cardiac function,and is worthy of popularization and application.